SAMN03290909
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.600
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.500
- INTERFERON_ALPHA_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.500
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- ALLOGRAFT_REJECTION+0.300
- ANDROGEN_RESPONSE+0.300
Top 10 suppressed
- BILE_ACID_METABOLISM-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- ESTROGEN_RESPONSE_EARLY-0.200
- MYOGENESIS-0.200
- P53_PATHWAY-0.200
- PEROXISOME-0.200
- WNT_BETA_CATENIN_SIGNALING-0.200
- XENOBIOTIC_METABOLISM-0.200
- ADIPOGENESIS-0.100
- APICAL_JUNCTION-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A18V-01A-11R-A12D-07 | — | E | 0.887 |
| 2 | TCGA-A2-A1G1-01A-21R-A13Q-07 | — | E | 0.884 |
| 3 | TCGA-AR-A0U4-01A-11R-A109-07 | — | E | 0.862 |
| 4 | c96595aa-4604-4ec6-8b54-c97b3543777e | — | — | 0.857 |
| 5 | TCGA-AR-A1AR-01A-31R-A137-07 | — | D | 0.852 |
| 6 | BS_4QW2S1Q8 | high-grade glioma | — | 0.851 |
| 7 | TCGA-XF-A9SY-01A-21R-A42T-07 | — | — | 0.841 |
| 8 | TCGA-C8-A27B-01A-11R-A169-07 | — | E | 0.835 |
| 9 | SRR29022839 | — | A | 0.831 |
| 10 | TCGA-FD-A3B3-01A-12R-A206-07 | — | — | 0.829 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.600 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |